Status:
WITHDRAWN
Effectiveness of the Diaphragm for HIV Prevention
Lead Sponsor:
University of California, San Francisco
Collaborating Sponsors:
Bill and Melinda Gates Foundation
Ibis Reproductive Health
Conditions:
HIV Infection
Eligibility:
FEMALE
18-49 years
Phase:
PHASE3
Brief Summary
The purpose of this trial is to determine whether using the diaphragm and a lubricant get can reduce women's risk of acquiring an HIV infection.
Detailed Description
This multi-site randomized, controlled trial will measure the effectiveness of the diaphragm in preventing heterosexual acquisition of HIV infection among women. This Phase III study is powered to det...
Eligibility Criteria
Inclusion
- Age 18 to 49 years old
- Sexually active (coital frequency at least four times per month on average)
- HIV negative based on testing within two weeks prior to enrollment
- Chlamydia trachomatis and Neisseria gonorrhoeae negative based on testing within 30 days prior to enrollment or if positive, completes treatment before enrollment
- Have a healthy cervix, as assessed by naked-eye speculum exam at enrollment
- Planning to live in the study area for the next 24 months
- Willing to be randomly assigned either to use or not use a latex diaphragm with lubricant gel during participation in the study, and to follow the protocol, including being tested for HIV and STIs
- Willing and able to give informed consent
Exclusion
- Known sensitivity or allergy to latex
- History of TSS (as suggested by current labeling for diaphragm use)
- Currently pregnant, or desiring to become pregnant in the next two years
- No cervix (total hysterectomy)
- Refuses treatment for diagnosed or suspected current STI and/or reproductive tract infection requiring treatment at enrollment
- Within six weeks of any pelvic surgery or last pregnancy outcome at the time of screening and enrollment
- Presence of clinically apparent lesion(s) with epithelial disruption at enrollment (may enroll after lesion(s) has healed, if otherwise eligible)
- Injected illicit drugs in the 12 months prior to screening and enrollment
- Blood transfusion or received blood products in 3 months prior to screening and enrollment
- Unable or unwilling to insert the diaphragm correctly
- Participation in any other clinical trial (including those of a vaginal product or barrier contraceptive). Verification by comparing participant lists to other concurrently running research studies may be conducted if necessary.
- Unable to speak English, Zulu, Shona, or Sotho
- Other conditions that, in the opinion of the investigator, would constitute contraindications to participation in the study or would compromise ability to comply with the study protocol, such as a major psychiatric disorder
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00121459
Start Date
September 1 2003
Last Update
March 4 2015
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Perinatal HIV Research Unit
Soweto, Gauteng, South Africa
2
Medical Research Council of South Africa
Durban, KwaZulu-Natal, South Africa
3
UZ-UCSF
Harare, Zimbabwe